Search by Drug Name or NDC

NDC 00074-1050-70 Skyrizi 150 mg/mL Details

Skyrizi 150 mg/mL

Skyrizi is a SUBCUTANEOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AbbVie Inc.. The primary component is RISANKIZUMAB.

MedlinePlus Drug Summary

Risankizumab-rzaa injection is used to treat moderate to severe plaque psoriasis (a skin disease in which red, scaly patches form on some areas of the body) in adults whose psoriasis is too severe to be treated by topical medications alone. Risankizumab-rzaa is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.

Related Packages: 00074-1050-70
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Risankizumab-rzaa Injection

Product Information

NDC	00074-1050
Product ID	0074-1050_7718dd85-622c-478e-ae9b-91e14a1373c6
Associated GPIs	9025057070E540
GCN Sequence Number	082262
GCN Sequence Number Description	risankizumab-rzaa SYRINGE 150 MG/ML SUBCUT
HIC3	L1A
HIC3 Description	ANTIPSORIATIC AGENTS,SYSTEMIC
GCN	49617
HICL Sequence Number	045699
HICL Sequence Number Description	RISANKIZUMAB-RZAA
Brand/Generic	Brand
Proprietary Name	Skyrizi
Proprietary Name Suffix	n/a
Non-Proprietary Name	risankizumab-rzaa
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	INJECTION
Route	SUBCUTANEOUS
Active Ingredient Strength	150
Active Ingredient Units	mg/mL
Substance Name	RISANKIZUMAB
Labeler Name	AbbVie Inc.
Pharmaceutical Class	Interleukin-23 Antagonist [EPC], Interleukin-23 Antagonists [MoA]
DEA Schedule	n/a
Marketing Category	BLA
Application Number	BLA761105
Listing Certified Through	2025-12-31

Package

NDC 00074-1050-70 (00074105070)

Pricing Information	N/A
NDC Package Code	0074-1050-70
Billing NDC	00074105070
Package	1 SYRINGE in 1 CARTON (0074-1050-70) / 1 mL in 1 SYRINGE
Marketing Start Date	2021-04-26
NDC Exclude Flag	N